Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Geert scrutinized
The alleged ‘case’ for experimental C-19 vaccination of children is merely based on silo mentality and immunological ignorance
GeertVandenBossche Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Continued mass vaccination will only push the evolutionary capacity of SARS-CoV-2 Spike protein beyond the Omicron version
Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.by G.
Keep looking at snapshots and you’ll never see where this pandemic is headed until it reaches its final destination.
GeertVandenBossche Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Virologist Geert Vanden Bossche Responds to Attacks From Dr. David Gorski
Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite. My name is Geert Vanden Bossche. I received my PhD in Virology at the University of Hohenheim, Germany, and I have held adjunct faculty appointments at universities in Germany and Belgium. I also have worked in R&D and vaccine development for GSK, Novartis, and Solvay Biologicals.
Why is the ongoing mass vaccination experiment driving a rapid evolutionary response of SARS-CoV-2?
Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite. Summary As Sars-CoV-2 entered a highly susceptible human population, it has initially been spreading rapidly and in an uncontrollable way. This already explains why Sars-CoV-2 has been evolving rather slowly with no substantial selection of fitness-enhancing mutations occurring over the first 10 months of the pandemic (i.e., between December 2019 and October 2020).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Geert
Contact Geert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack